Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;12(3):1419-1437.
doi: 10.1007/s40123-023-00691-3. Epub 2023 Mar 2.

Artificial Intelligence for Diabetic Retinopathy Screening Using Color Retinal Photographs: From Development to Deployment

Affiliations
Review

Artificial Intelligence for Diabetic Retinopathy Screening Using Color Retinal Photographs: From Development to Deployment

Andrzej Grzybowski et al. Ophthalmol Ther. 2023 Jun.

Abstract

Diabetic retinopathy (DR), a leading cause of preventable blindness, is expected to remain a growing health burden worldwide. Screening to detect early sight-threatening lesions of DR can reduce the burden of vision loss; nevertheless, the process requires intensive manual labor and extensive resources to accommodate the increasing number of patients with diabetes. Artificial intelligence (AI) has been shown to be an effective tool which can potentially lower the burden of screening DR and vision loss. In this article, we review the use of AI for DR screening on color retinal photographs in different phases of application, ranging from development to deployment. Early studies of machine learning (ML)-based algorithms using feature extraction to detect DR achieved a high sensitivity but relatively lower specificity. Robust sensitivity and specificity were achieved with the application of deep learning (DL), although ML is still used in some tasks. Public datasets were utilized in retrospective validations of the developmental phases in most algorithms, which require a large number of photographs. Large prospective clinical validation studies led to the approval of DL for autonomous screening of DR although the semi-autonomous approach may be preferable in some real-world settings. There have been few reports on real-world implementations of DL for DR screening. It is possible that AI may improve some real-world indicators for eye care in DR, such as increased screening uptake and referral adherence, but this has not been proven. The challenges in deployment may include workflow issues, such as mydriasis to lower ungradable cases; technical issues, such as integration into electronic health record systems and integration into existing camera systems; ethical issues, such as data privacy and security; acceptance of personnel and patients; and health-economic issues, such as the need to conduct health economic evaluations of using AI in the context of the country. The deployment of AI for DR screening should follow the governance model for AI in healthcare which outlines four main components: fairness, transparency, trustworthiness, and accountability.

Keywords: Artificial intelligence; Deep learning; Deployment; Diabetic retinopathy; Diabetic retinopathy screening; Machine learning; Retinal photographs.

PubMed Disclaimer

Conflict of interest statement

All authors declare that they have no competing interests. The views expressed in the publication are those of the authors. Andrzej Grzybowski has received grants from Alcon, Bausch&Lomb, Zeiss, Teleon, J&J, CooperVision, and Hoya; has received lecture fees from Thea, Polpharma, and Viatris; and is a member of the advisory boards of Nevakar, GoCheckKids, and Thea. Panisa Singhanetr has nothing to disclose. Onnisa Nanegrungsunk has received reimbursement from Novartis for medical writing (for studies other than the present study; has received lecture fees from Allergan; has received financial support for attending educational meetings from Bayer and Novartis; and is on the advisory board of Roche. Paisan Ruamviboonsuk has received grants from Roche and Novartis; is a consultant for Bayer, Novartis, and Roche; and has received speaker fees from Novartis, Roche, Bayer, and Topcon.

Similar articles

Cited by

References

    1. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes-global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107–111. doi: 10.2991/jegh.k.191028.001. - DOI - PMC - PubMed
    1. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843. - DOI - PubMed
    1. GBD 2019 Blindness and Vision Impairment Collaborators Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e144–e160. doi: 10.1016/S2214-109X(20)30489-7. - DOI - PMC - PubMed
    1. Teo ZL, Tham YC, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580–1591. doi: 10.1016/j.ophtha.2021.04.027. - DOI - PubMed
    1. The Diabetic Retinopathy Study Research Group Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. Ophthalmology. 1981;88(7):583–600. - PubMed

LinkOut - more resources